Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

作者：Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Ф. И. Нагимова, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Andrade‐Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen‐Ristea, Veerle Van Eygen, Herta Crauwels, Susan L. Ford, Christine L. Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark S. Shaefer, David A. Margolis, Kimberly Y. Smith, Simon Vanveggel, William Spreen · 发表于：The Lancet · 年份：2020 · DOI：10.1016/s0140-6736(20)32666-0 · 被引用次数：375 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、HIV-related health complications and treatments